Equity Overview
Price & Market Data
Price: $8.30
Daily Change: +$0.45 / 5.42%
Range: $7.55 - $8.30
Market Cap: $1,256,273,792
Volume: 2,042,290
Performance Metrics
1 Week: 10.18%
1 Month: 4.91%
3 Months: -1.00%
6 Months: -30.52%
1 Year: 55.67%
YTD: -7.49%
Company Details
Employees: 274
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.